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Abstract. The aim of this study was to evaluate in detail the 
histopathological characteristics of endarterectomized carotid 
atherosclerotic lesions in symptomatic versus asymptomatic 
patients. Twenty carotid lesions, 10 from asymptomatic and 
10 from symptomatic patients who underwent carotid endar-
terectomy were classified according to histomorphological 
features. Samples were analyzed for intraplaque localization 
and for the expression of proteins associated with inflamma-
tion, such as CD68, interleukin (IL)-1β, tumor necrosis factor-α 
(TNF-α), pentraxin-3 (PTX-3), nuclear factor-κB (NF-κB), 
C-reactive protein (CRP) and transforming growth factor-β 
(TGF-β), as well as for proteins associated with vascular 
remodelling, such as matrix-metalloproteinase-9 (MMP-9), 
glycophorin A (GYPA), osteoprotegerin (OPG), vascular cell 
adhesion molecule-1 (VCAM-1), endothelin-1 (ET-1), vascular 
endothelial growth factor (VEGF) and vascular smooth muscle 
cell actin (VSMA). Corresponding expression scores were 
compared between the symptomatic and asymptomatic patients 
and evaluated statistically. The expression of all 14 evaluated 
markers was significantly elevated in the border zone adjacent 
to the mixed plaque compared with the unaffected control area 
of the same sample (p<0.016). The expression scores of GYPA 
and OPG were significantly higher in the border zones around 
the calcified (GYPA, p=0.035; OPG, p=0.043) and mixed 
(GYPA, p<0.001; OPG, p=0.007) plaque zones of symptomatic 
patients compared to asymptomatic patients. No difference 
in expression scores was observed for any of the analyzed 
inflammatory marker proteins between the border zones of 
symptomatic and asymptomatic patients. In conclusion, the 
increased expression of GYPA, indicating intraplaque hemor-
rhage, and OPG, indicating the transdifferentiation of vascular 
cells, in carotid atherosclerotic lesions may be associated with 
an increased risk of plaque instability.
Introduction
The therapeutic indication of asymptomatic carotid artery 
stenosis is based on the degree of stenosis, which statistically 
correlates with the risk of stroke (1,2). According to current 
concepts, the predominant pathological substrate of cerebral 
ischemic events results from the embolization of unstable 
or thrombogenic atherosclerotic plaque. Until now, reliable 
clinical criteria differentiating between stable and risk prone 
carotid plaque do not exist.
In addition to extensive image analysis, several biomarkers 
have been examined, aiming to find predictive factors that 
indicate an elevated risk of plaque instability and consecutive 
embolization. Some prominent morphological features, such 
as vascularization, the amount of necrotic core, thin fibrous 
cap, intraplaque hemorrhage or increased intima-media thick-
ness (IMT) are associated with plaque vulnerability (3).
However, the cellular events leading to plaque rupture are 
not yet fully understood. To further characterize the biological 
activity of plaque and the areas adjacent to plaque, in this 
study, we assessed the expression and localization of proteins 
with a potential role in the pathogenesis of atherosclerosis in 
correlation with qualitatively defined plaque components. In 
contrast to several other previously described plaque models 
focusing on plaque area only (4), our study introduces a new 
model by additionally investigating surrounding border zones 
neighboring different plaque areas. Plaque from 20 patients 
that had undergone carotid endarterectomy (CEA) were histo-
logically mapped and stained by immunohistochemistry for 
marker proteins associated with matrix remodeling, such as 
matrix-metalloproteinase-9 (MMP-9), glycophorin A (GYPA), 
osteoprotegerin (OPG), vascular cell adhesion molecule-1 
(VCAM-1), endothelin-1 (ET-1) and vascular endothelial 
growth factor (VEGF), as well as for markers associated 
with inflammation, such as tumor necrosis factor‑α (TNF-α), 
transforming growth factor-β (TGF-β), interleukin-1β (IL-1β), 
C-reactive protein (CRP), pentraxin-3 (PTX-3), nuclear 
factor-κB (NF-κB) and CD68. Vascular smooth muscle cell 
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actin (VSMA) was used for the identification of vascular 
smooth muscle cells (VSMCs).
Emerging evidence indicates that the increased expression 
of MMP-9 is involved in plaque destabilization (5). MMP-9 
belongs to a family of enzymes that promotes the degradation 
of extracellular matrix components, such as elastin, proteogly-
cans and laminin and is associated with vascular remodeling 
and atherogenesis. MMP-9 is produced by macrophages, 
macrophage foam cells and VSMCs and has been shown to 
stimulate the production of TNF-α and IL-1, which in turn 
promotes inflammation (6).
GYPA, a protein specific to erythrocytes, and OPG are 
considered markers for structural damage. GYPA has been 
reported to indicate intraplaque hemorrhage and to be asso-
ciated with necrotic cores and macrophage infiltration in 
coronary atheromas (7). OPG is a glycoprotein that acts as a 
receptor for the ‘receptor activator of NF-κB’ ligand. Plasma 
OPG levels are elevated in patients with vascular disease and 
the OPG concentration in carotid plaque is associated with the 
prevalence of artery calcium and plaque instability (8,9).
VCAM-1 plays a role in initiating atherosclerotic cascades 
by mediating the firm adhesion between macrophages and 
endothelial cells (10). Its expression in activated endothelial 
cells is induced by TGF-β (11), IL-1 (12) and by cholesterol 
accumulation (13).
VEGF is a key player in angiogenesis and neovasculariza-
tion as well as in vascular permeability or thrombogenicity (14). 
By the initiation of neovascularization, VEGF also plays a role 
in intraplaque microvessel formation and restenosis (15).
ET-1 is induced in endothelial cells by biomechanical 
stimuli, hypoxemia, hormones or cytokines. It stimulates the 
contraction and growth of smooth muscle cells (16).
TNF-α and IL-1β are pro-inflammatory cytokines that 
are released from activated macrophages. PTX-3 is a soluble 
receptor of the pattern recognition type, labeling cellular debris 
and pathogens for phagocytosis by macrophages. Accordingly, 
it is found in macrophage foam cells which play a key role in 
atherosclerosis, as well as in circulating blood. Elevated plasma 
levels of PTX-3 have recently been shown to be associated with 
plaque vulnerability (17). Elevated plasma levels of CRP induce 
pro-inflammatory changes by the activation of peripheral 
leukocytes with the ensuing secretion of plaque-destabilizing 
mediators, such as MMP-9 (18).
The scavenger receptor, CD68, that interacts with oxidized 
low-density lipoprotein (oxLDL) amongst others, is a heavily 
glycosylated transmemberane protein that is predominantly 
expressed in monocytes and macrophages. Upon interaction 
with oxLDL, macrophages transform into foam cells. The 
presence of a high CD68-positive macrophage count has 
been demonstrated to be associated with plaque destabiliza-
tion (19,20).
Patients and methods
Patients. Carotid artery plaque obtained from patients 
who had undergone CEA was randomly selected from 
the vascular tissue bank of the Department of Vascular 
Surgery/National Center for Tumor Diseases (NCT), University 
of Heidelberg, Heidelberg, Germany. The study population 
included 20 specimens, 10 from asymptomatic and 10 from 
symptomatic patients. Indications for CEA were high-grade 
internal carotid artery stenosis (as determined by ultrasound) 
for asymptomatic patients and transient ischemic attack (TIA), 
amaurosis fugax (AF) or ischemic stroke for symptomatic 
patients. Neurological events had occurred within 6 months 
prior to surgery. Clinical data, including medication, blood 
work and risk factors for atherosclerosis were recorded for all 
patients (Table Ⅰ). Patients with atrial fibrillation were excluded. 
A neurologist examined all symptomatic patients according to 
clinical standards and the study followed ethical guidelines.
Tissue processing. After dissection of the internal carotid 
artery from the bifurcation, the intact specimen was harvested 
by a vascular surgeon (routine eversion technique) (Fig. 1). 
The fresh carotid eversion specimen was rinsed with saline 
to remove surface blood, and defined proximal sections were 
divided into 3 tissue segments (rings of approximately 3 mm 
thickness): 2 segments were formalin‑fixed and embedded in 
paraffin according to standard procedures for conventional 
histological analysis and immunohistochemistry. A third 
segment was shock‑frozen and stored in a freezer at ‑80˚C.
Histological graduation. For the assessment of morphological 
features, the American Heart Association (AHA) classification 
was adapted for advanced carotid atherosclerotic lesions (21).
Plaque characterization and definition of morphological 
zones. Based on the morphologial examination, we defined 
3 different zones within the atherosclerotic lesions (Fig. 2A): 
plaque (zone 1), border zone (zone 2) and normal vessel wall 






    Male 7 10
    Female 3
  Mean age (years) 68.6±9.9 73.7±8.7
  Mean BMI (kg/m²) 26.2±3.7 25.9±3.8
  Mean degree of stenosis (%) 81.5±8.2 81.5±14.2
Risk factors
  Arterial hypertension 9 10
  Diabetes mellitus 2 1
  Nicotin 1 2
  Hyperlipidemia 6 8
Medication
  Acetylsalicylic acid  10 9
  Statins 6 9
  Oral antidiabetics/insulin 2 1
  Anti-hypertonics 9 9
BMI, body mass index.
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(zone 3, control). The plaque zone was divided in 3 major 
subtypes: calcified (1a), lipid‑rich (1b) and mixed type (1c). 
Similarly, the border zone was classified as bordering to calci-
fied (2a), lipid‑rich (2b) or mixed (2c) plaque. The unaffected 
vessel wall of the same sample (zone 3) was used as the control 
for comparison. To determine the dimension of the different 
morphological areas, a grid was applied on each transverse 
sliced sample (square measure of 9033.39 µm² per grid unit) 
(Fig. 2B). Analysis was performed using a microscope (CX40; 
Olympus, Tokyo, Japan) at an original magnification of x200 
and a camera (QImaging, Surrey, BC, Canada). Each grid unit 
was assigned to a plaque, border or control zone. Corresponding 
protein expression, as detected by immunohistochemistry, was 
semi-quantitatively scored by 2 independent investigators 
unaware of the clinical history of the patient samples (for score 
evaluations see following section). The plaque zone (zone 1) 
was characterized by necrotic areas, fibrous tissue, large 
amounts of calcium and cholesterol. Areas with mixed features 
demonstrated noticeable calcification and cholesterol-rich 
areas and signs of surface disruption or fissures were observed 
(Fig. 2G and H). The main characteristics of zone 2 were large 
amounts of inflammatory cells, neovascularization and deal-
location of the intima and media, while zone 3 represented 
intact vascular tissue with a clear separation of the intima and 
media plus a significantly lower amount of inflammatory cells 
(ratio 1:10 compared to zone 2).
Immunohistological analysis
Staining procedures and antibodies. For the immunohisto-
chemical detection of protein expression, serial 4-µm-thick 
sections were prepared from each paraffin‑embedded tissue 
specimen throughout the plaque at the level of the highest degree 
of stenosis. After deparaffination and rehydration, the samples 
were pre-treated according to individually optimized protocols 
(detailed protocols and antibody dilutions are available upon 
request). The following unconjugated primary antibodies were 
used for detection: monoclonal mouse anti-MMP-9 was obtained 
Figure 1. (A) Typical plaque cylinder, harvested using eversion technique. 
(B) Sliced plaque cylinder. (C) Proximal slice (used for examinations).
Figure 2. Spatial resolution and zonal mapping of different carotid plaque 
types. Graphic presentation of (A) zones and (B) grid‑units: 1a, calcified 
plaque; 1b, lipid‑rich plaque; 1c, mixed plaque; 2a, border zone to calcified 
plaque; 2b, border zone to lipid-rich plaque; 2c, border zone to mixed plaque. 
(C-H) Representative samples of carotid artery wall exemplifying zonal map-
ping. (C) Trichrome‑stained control zone. (D) Trichrome staining of a calcified 
plaque and border zone. (E) Trichrome staining showing lipid-rich plaque and 
border zone. (F) Mixed plaque and border zone. (G) Hematoxylin-stained 
mixed plaque and border zone; the area of calcification is marked with an 
asterisk (calcified material is partly detached). (H) Mixed plaque and border 
zone as shown in (G), immunohistochemically staining for CD68 (red). 
Original magnification; (C) x20, (D‑F) x40, (G and H) x100.
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from Calbiochem (Merck, Darmstadt, Germany); polyclonal 
rabbit anti-GYPA, rabbit anti-IL1β, rabbit anti-NF-κB, rabbit 
anti-TGF-β, monoclonal mouse anti-VCAM, polyclonal rabbit 
anti-VEGF and polyclonal rabbit anti-OPG were obtained from 
Santa Cruz (Heidelberg, Germany); rabbit monoclonal anti-
OPG was purchased from Epigenomics - Biomol (Hamburg, 
Germany), and monoclonal mouse anti-VSMA was from 
Sigma (Taufkirchen, Germany); monoclonal mouse anti-CD68 
was from USBiological - Biomol (Hamburg, Germany), poly-
clonal sheep anti-CRP was from Biotrend (Koeln, Germany), 
polyclonal rabbit anti-ET-1 was from Chemicon (Nuernberg, 
Germany), polyclonal rabbit anti-TNF-α was from Genzyme 
(Neu-Isenburg, Germany), and polyclonal rabbit anti-PTX-3 
was from Alexis Biochemicals (Loerrach, Germany). The 
slides were washed 2x5 min in Tris-buffer and exposed to a 
biotinylated antibody [MultiLink, HK 340-9K (5%); BioGenex, 
San Ramon, CA, USA] for 20 min. After washing again for 
2x5 min in Tris-buffer, the samples were incubated with 
peroxidase (horseradish peroxidase conjugate) for 20 min, 
washed again for 2x5 min in Tris-buffer and stained with Fast 
Red (Zytomed Systems, Berlin, Germany). Colour development 
was stopped by the addition of water and the sections were 
finally counterstained with hematoxylin (Dako REAL, Dako 
North America, Inc., Capinteria, CA, USA) 1:3 in distilled 
aqua. For the negative controls, the application of the primary 
antibody was omitted. Masson-Goldner trichrome staining was 
used according to standard procedures for the visualization of 
different connective tissue components.
Expression score. The level of antigen expression was 
determined semi-quantitatively by a score composed of inten-
sity and quantity. Data for the intensity ran from 0, no staining; 
>1, faint positive staining and 2, moderate positive staining 
to 3, strong positive staining. Data for the quantity ran from 
0, no staining; 1, <10%; 2, 10-50%; 3, 51-80% and 4, >80% of 
structures positively stained within the field of view. The score 
was built by the multiplication of both results (22,23). To avoid 
observation bias, we first investigated the different zones in 
all the samples, not discriminating between symptomatic or 
asymptomatic patients. During a second revision, we focused 
on the zonal distribution to differentiate between symptomatic 
and asymptomatic patients.
Statistical analysis. Statistical analysis was performed using 
SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). 
For a comparison of zonal protein scores between border 
zones and control zones within the same sample, quantita-
tive non-parametric continuous variables were expressed as 
medians and compared by using the Wilcoxon matched-pairs 
signed rank test. The Mann-Whitney U test was applied to 
compare the expression score of each marker derived from 
different border zones (adjacent to calcified, lipid‑rich or mixed 
plaque) between asymptomatic and symptomatic patients; 
a value of p<0.05 was considered to indicate a statistically 
significant difference.
Results
Patient characteristics. As shown in Table Ⅰ, the mean age 
of the patients was 68.6±9.9 years for the asymptomatic and 
73.7±8.7 years for the symptomatic patients. Neurological 
events of the symptomatic patients had occurred within the 
last 6 months with a history of recent occurrence of cerebral 
symptoms [7 patients with non-disabling ischemic stroke 
(Rankin 1-3), 2 with TIA and 1 with AF]. Nine asymptomatic 
and 10 symptomatic patients had hypertension, 6 asymptomatic 
and 8 symptomatic were afflicted with hypercholesterolemia. 
In total, 3 patients were diabetic and 3 had a history of 
>20 ‘pack years’ of nicotine abuse. The mean body mass index 
was 26.2±3.7 kg/m2 for the asymptomatic and 25.9±3.8 kg/m2 
for the symptomatic patients.
Morphological plaque features according to AHA clas-
sification. The assessment of morphological plaque features 
was carried out as previously described in the study by Stary 
et al (21). As visualized by trichrome staining, all specimens 
showed severe lesions with calcification, plaque rupture, 
intra-plaque hemorrhage or fissures equivalent to type V 
and VI lesions, according the AHA criteria. Four out of the 
10 asymptomatic but only 1 out of the 10 symptomatic patients 
had type V lesions. This shows a tendency toward the presence 
of type VI lesions in symptomatic patients, without statistical 
significance, however.
Spatial resolution and differentiation of zones with distinc-
tive morphological features. All types of plaque zones and 
border zones, namely calcified, lipid-rich and mixed type, 
were observed in the atherosclerotic lesions from the symp-
tomatic and asymptomatic patients. The plaque and border 
zone accounted for approximately 72% (±1.3) of the vessel 
wall area, whereas the control zone accounted for 28% (±1.3) 
of the total cross sectional area. Zone 1a (calcified plaque) 
ranged between 0 and 29%, zone 1b (lipid-rich plaque) ranged 
between 0 and 40% and zone 1c (mixed plaque) ranged 
between 25 and 93% of the plaque area. The same spatial 
distribution was observed in the border zones. No difference 
in zonal expansion was observed between the symptomatic or 
asymptomatic patients.
Zonal distribution of protein expression according to immu-
nohistochemical analysis. In general, all proteins tested were 
found to be predominantly expressed in the border zones 
(zone 2), touching or surrounding different plaque types. Except 
for VSMA, indicating the presence of smooth muscle cells in 
the vascular media, little protein expression was observed in 
the control zones (zone 3), whereas almost no protein expres-
sion was present within the plaque zones (zone 1). Statistical 
analysis revealed significantly elevated expression scores of 
all tested proteins in the border zones compared to control 
zones. Within the border zones, those touching mixed plaque 
(zone 2c) presented significantly higher protein expression 
scores than the border zones touching pure calcified (zone 2a) 
or pure lipid-rich (zone 2b) plaque (Fig. 3). As indicated by the 
high VSMA expression, the highest expression of the majority 
of proteins tested (except for CRP) overlapped with the pres-
ence of a high density of smooth muscle cells in zone 2c.
Furthermore, inflammatory markers, such as CD68, 
NF-κB, IL-1β, TNF-α and PTX-3, representing the presence of 
activated macrophages, displayed significantly higher expres-
sion scores in zone 2c compared to the control zone (Fig. 2G, H 
and Fig. 3). This indicates that macrophage infiltration is more 
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prominent in the border zones adjacent to mixed plaque than in 
other border zones.
By contrast, the expression score of the inflammatory 
protein, CRP, was highest in zone 2a, touching calcified plaque, 
followed by border zones touching mixed plaque (zone 2c), its 
epxression was still significantly higher in these zones compare 
to the control zones. Of note, CRP was completely absent from 
the border zone adjacent to lipid‑rich plaque (zone 2b). Similar 
to CRP, the ET‑1 expression score was significantly reduced in 
zone 2b compared to the control and other border zones.
Border zones touching calcified plaque (zone 2a) revealed 
a statistically significant higher expression score of GYPA, 
MMP-9, OPG, IL-1β, CRP and CD68 compared to the control 
zones (Figs. 3 and 4). In addition to macrophage infiltration, 
this points to greater intraplaque hemorrhage, matrix degen-
eration and presumably ongoing calcification in these areas. 
By contrast, the VSMA expression score was significantly 
reduced, indicating a reduced number of VSMCs around calci-
fied plaque.
Comparison of protein expression scores between symptom-
atic and asymptomatic patients. The observation that the 
expression of inflammatory markers and proteins involved in 
vascular remodeling was most prominent in the border zones 
touching mixed plaque, suggested that these plaque types 
may be more vulnerable. Accordingly, we were interested 
in whether some of these protein scores differ significantly 
between symptomatic and asymptomatic patients.
No difference in expression scores was observed for any of 
the inflammatory marker proteins (CD68, IL‑1β, NF-κB, CRP, 
PTX-3, TNF-α and TGF-β) between the individual border zones 
of symptomatic and asymptomatic patients (data not shown).
By contrast, the scores of some marker proteins associated 
with vessel wall remodeling differed significantly between 
the asymptomatic and symptomatic patients. The expression 
scores of GYPA in the border zones around the calcified and 
mixed plaque areas were slightly but statistically significantly 
higher in the symptomatic compared to the asymptomatic 
patients (Fig. 5). The same tendency was observed in the border 
zones around the lipid-rich plaque zones, without reaching 
statistical significance, however. In addition, the expression 
scores of OPG were significantly higher in all border zones 
of symptomatic compared to asymptomatic patients, inde-
pendent of the adjacent plaque type (Fig. 5). No difference 
was observed for any of the remaining markers tested (ET-1, 
MMP-9, VCAM-1, VEGF and VSMA; data not shown).
Discussion
It is well accepted that atherosclerotic lesions represent complex 
heterogeneous structures composed of connective tissue, calci-
fication, inflammatory cells and lipids in proportions differing 
from plaque to plaque (24-26). Increasing evidence suggests 
that individual plaque morphology and plaque composition 
contribute to the vulnerability and risk of rupture, in addition 
to the grade of stenosis (27,28). Consequently, a histopatho-
logical staging (AHA classification) was introduced for the 
classification of atherosclerotic coronary lesions (21,29) that 
is likewise applied to carotid lesions. Furthermore, a growing 
number of studies have reported the analysis of single proteins 
expressed in carotid lesions to be used as biomarkers for the 
evaluation of plaque rupture and stroke risk at the early stages 
of disease. However, little progress has been made to achieve 
this target. In addition, the contribution of these proteins to 
Figure 3. Box-Whisker-Plots showing expression scores derived from immunohistochemical analysis of all carotid lesions, irrespective of patient symptoms. 
Expression score of zones 2a, b and c, respectively, were compared to the control zones. Boxes indicate the median, as well as the upper (75%) and lower (25%) 
quartile. *p<0.05; **p<0.01.
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Figure 4. Representative examples of internal carotid artery (ICA) lesions for comparison of plaque border zones with control zones. Original magnification, x200. 
(A) Trichrome staining of a control zone within an ICA sample derived from a symptomatic patient. (B) Vascular smooth muscle cell actin (VSMA) expression 
and (C) limited matrix-metalloproteinase-9 (MMP-9) expression in the same area as shown in (A). (D-F) Corresponding mixed plaque zone of the same patient, 
showing trichrome staining (D), reduced VSMA expression (E) and high MMP-9 expression (F). (G-I) Control zone from the ICA lesion of a second symptomatic 
patient showing trichrome staining (G), VSMA expression (H) and endothelial vascular cell adhesion molecule (VCAM) expression (I, arrow). (J-L) Corresponding 
lipid-rich plaque zone of the same sample as in (G-I), showing trichrome staining (J), VSMA expression (K) and increased VCAM expression (L) in the border zone 
to lipid-rich plaque. *Calcified area; Lu, lumen; Lip, lipid‑rich plaque. Expression of individual marker proteins is indicated by red immunohistochemical staining.
  A   B
Figure 5. Representative examples of internal carotid artery (ICA) lesions from asymptomatic versus symptomatic patients. (A) Box-Whisker-Plots showing 
scores of glycophorin A (GYPA) and osteoprotegerin (OPG) expression in plaque border zones of asymptomatic (as) and symptomatic (s) patients, respectively. 
Boxes indicate the median, as well as the upper (75%) and lower (25%) quartile. *p<0.05. (B) Immunohistochemical analysis of GYPA and OPG expression 
(red staining) in carotid lesions derived from asymptomatic and symptomatic patients, respectively. Correspondent immunohistochemical staining of non-
atherosclerotic arterial walls is shown for control. Original magnification, x100.
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plaque instability is controversially discussed in the literature 
and the biological mechanisms leading to plaque rupture are 
not yet completely understood (30).
To gain deeper insight into carotid plaque composition 
of asymptomatic and symptomatic patients, in this study, 
we introduced a new approach to analyze carotid lesions in 
greater detail by morphologically subdividing the samples into 
different zones of (cell-free) plaque, border zones touching the 
plaque material and a control zone. Using this zoning system, 
we scored the expression of 7 inflammatory marker proteins 
and 7 proteins associated with remodeling of the artery wall in 
endarterectomized carotid samples from asymptomatic versus 
symptomatic patients at punctum maximum of stenosis.
Our findings add to the body of research from previous 
studies, which predominantly focused on differential gene/
protein expression in carotid lesions as a whole (27,31), or 
within selected areas, such as calcification (32) or the plaque 
shoulder without differentiating systematically between plaque 
components. Moreover, the majority of studies on atheroscle-
rotic plaque heterogeneity and instability have been performed 
on coronary artery lesions. Although it has been suggested that 
carotid lesions follow a pattern of development and progres-
sion similar to coronary arteries, and may encounter the same 
mechanisms leading to rupture, this hypothesis is still contro-
versially discussed (25).
Our immunohistochemical analysis revealed a signifi-
cantly elevated protein expression of all markers investigated 
in the border zone adjacent to plaque, whereas border zones 
touching mixed plaque displayed the highest scores. Thus, the 
area adjacent to a combination of both calcification and lipid 
deposit showed the highest biological activity with respect 
to inflammation and tissue remodeling, irrespective of the 
patient's symptomatic features.
Inflammation is considered a key mechanism in human 
atherosclerotic plaque vulnerability and disruption (33). 
However, in our study, the grade of inflammation and macro-
phage density, as assessed by the expression scores of CD68, 
IL-1β, NF-κB, TNF-α, CRP, PTX-3 and TGF-β, did not differ 
between the samples from asymptomatic and symptomatic 
patients. In addition, the expression of markers indicating the 
recruitment and adhesion of inflammatory cells (VCAM‑1), 
matrix degeneration (MMP-9) and neovascularization (VEGF) 
was similar in both patient groups.
By contrast, GYPA and OPG expression, despite being a 
rare event, was significantly more prominent in lesions from 
our symptomatic patients. Increased levels of GYPA were 
found in border zones around calcified and mixed plaque in 
patients who presented with neurological events. The differ-
ence was likewise observed in border zones around lipid-rich 
plaque without reaching statistical significance. Although our 
results are based on a relatively small sample size, this indi-
cates that intraplaque haemorrhage may be involved in plaque 
vulnerability. Our data is in line with findings from coronary 
atheromas, where larger levels of GYPA were associated with 
advanced plaque instability (7). Moreover, we previously 
demonstrated that deposits of erythrocyte membrane-derived 
material (as assessed by GYPA expression) was significantly 
more pronounced in the coronary intima of patients with 
chronic renal disease compared to non-renal patients (23). 
Finally, GYPA expression has recently been shown to correlate 
with thin fibrous cap and the clinical risk of CEA in a study 
using a CEA risk classification, which is independent of the 
symptomatic events if the patients (34). Based on their results, 
the authors recommended identifying patients with intraplaque 
haemorrhage by improved imaging and by performing CEA in 
those patients to avoid neurologic events.
Of note, we identified OPG expression scores to be signifi-
cantly elevated in all types of border zones in our group of 
symptomatic patients compared to asymptomatic patients. The 
role of OPG in vascular calcification and atherosclerosis is 
not yet clear. Several in vitro studies and animal models have 
suggested that OPG inhibits vascular calcification, whereas 
serum OPG levels have been associated with an increased risk 
of cardiovascular disease in clinical studies (35). OPG has 
been reported to be expressed in the normal vascular wall by 
endothelial and VSMCs. Moreover, increased OPG immuno-
reactivity and mRNA expression have been localized to areas 
surrounding calcification in the medial layer of Mönckeberg's 
sclerosis and areas adjacent to calcified neointimal lesions in 
carotid atherosclerotic arteries (36). Our data, demonstrating 
an increased OPG expression around different types of plaque 
not restricted to calcification, point to a more complex mecha-
nism of OPG activity in vascular remodelling that requires 
further investigation. In particular, it would be of interest to 
elucidate its role in plaque instability.
In conlcusion, in this study, we present evidence that intra-
plaque hemorrhage and OPG expression in areas touching 
mixed plaque that are composed of calcified and lipid-rich 
components, may be associated with plaque instability and 
subsequent neurological events in patients with carotid lesions 
independent of AHA classification. This argues for the need of 
a more detailed plaque analysis in non-symptomatic patients; for 
example, by the development of advanced imaging procedures 
that may aid in the identification of hemorrhage in these patients.
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